感染

订阅

MedSci主页 / 所有栏目 / 感染

新型抗TNFα抗体片段治疗眼前段炎症

2019-01-06 MedSci MedSci原创

眼前段炎症抗TNFα抗体Oculis
关注

Oculis是一家开发下一代局部眼科治疗药物的临床阶段生物制药公司，Oculis已签署协议，授权诺华公司推出一种新型局部抗TNFα抗体，该化合物名为LME 636，由专有的局部递送单链抗体片段技术给药。

Oculis是一家开发下一代局部眼科治疗药物的临床阶段生物制药公司，Oculis已签署协议，授权诺华公司推出一种新型局部抗TNFα抗体，该化合物名为LME 636，由专有的局部递送单链抗体片段技术给药。在诺华生物医学研究所进行的三项临床试验显示了LME 636的有效性和安全性，这些研究证明了LME 636可以用于治疗眼前段炎症，包括干眼症。眼前段包括角膜，巩膜、虹膜等，此部分炎症如果影响房角组织，或炎症渗出影响房水成分，都会使房水外流受阻，最终导致眼压升高。

肿瘤坏死因子 α（TNFα） 是一种多功能细胞因子，参与细胞的凋亡和存活、炎症反应、自身免疫等重要的生理过程，在类风湿性关节炎、克罗恩病和银屑病等疾病的发生发展中扮演重要角色。这使得靶向 TNFα 的治疗性药物研发成为这些疾病防治研究领域的热点，其中尤以抗TNFα抗体的效果最为显著。但在眼科炎症领域，对抗TNFα抗体的研究较少，而LME 636有可能成为第一款用于眼科炎症的抗TNFα抗体片段。


原始出处：

http://www.firstwordpharma.com/node/1615878?tsid=4#axzz5bnF206kJ

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1995761, encodeId=b2161995e6167, content=<a href='/topic/show?id=ba231e5989a' target=_blank style='color:#2F92EE;'>#TNFα#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17598, encryptionId=ba231e5989a, topicName=TNFα)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sun Nov 03 11:24:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670771, encodeId=5a6a16e0771f0, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Feb 01 00:24:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401710, encodeId=23721401e1021, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Tue Jan 08 12:24:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-11-03 gongliu

    #TNFα#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1995761, encodeId=b2161995e6167, content=<a href='/topic/show?id=ba231e5989a' target=_blank style='color:#2F92EE;'>#TNFα#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17598, encryptionId=ba231e5989a, topicName=TNFα)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sun Nov 03 11:24:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670771, encodeId=5a6a16e0771f0, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Feb 01 00:24:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401710, encodeId=23721401e1021, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Tue Jan 08 12:24:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-02-01 mfx808

    #抗TNF#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1995761, encodeId=b2161995e6167, content=<a href='/topic/show?id=ba231e5989a' target=_blank style='color:#2F92EE;'>#TNFα#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17598, encryptionId=ba231e5989a, topicName=TNFα)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sun Nov 03 11:24:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670771, encodeId=5a6a16e0771f0, content=<a href='/topic/show?id=abd35513ed5' target=_blank style='color:#2F92EE;'>#抗TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55137, encryptionId=abd35513ed5, topicName=抗TNF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7dc326754916, createdName=mfx808, createdTime=Fri Feb 01 00:24:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401710, encodeId=23721401e1021, content=<a href='/topic/show?id=17e21e57943' target=_blank style='color:#2F92EE;'>#TNF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17579, encryptionId=17e21e57943, topicName=TNF)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqjVbfRD4f4vibEcZVcvato8Qib1gGtZJiayXCMFgHrkeErSiaxdYMiabKGxY2an9muxWCkUJbjFPViaC6A/132, createdBy=e4fb2361580, createdName=snowpeakxu, createdTime=Tue Jan 08 12:24:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-08 snowpeakxu

    #TNF#

    0